tenofovir has been researched along with darunavir in 94 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.06) | 29.6817 |
| 2010's | 66 (70.21) | 24.3611 |
| 2020's | 27 (28.72) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Susman, E | 1 |
| Baraboutis, IG; Georgiou, O; Kotsianopoulou, M; Papastamopoulos, V; Samarkos, M; Skoutelis, AT; Vrionis, E | 1 |
| Back, D; Dickinson, L; Erlwein, OW; Garvey, L; Latch, N; Mackie, NE; McClure, MO; Scullard, G; Walsh, J; Winston, A | 1 |
| Sax, PE | 1 |
| DeJesus, E; Kakuda, TN; Lalezari, JP; Osiyemi, OO; Ruane, PJ; Ryan, R; Witek, J | 1 |
| Corbett, C; De Smedt, G; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Peeters, MP; Schöller-Gyüre, M; Snoeck, E; Vingerhoets, J; Vis, P; Wade, JR; Woodfall, BJ | 1 |
| Arribas, JR; Hill, A; Moecklinghoff, C; Pulido, F; Van Delft, Y | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Lavreys, L; Picchio, G; Van de Casteele, T | 1 |
| Aboh, S; Bosivert, N; Duke, N | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Acosta, EP; Barreca, ML; Chirullo, B; Collins, M; Della Corte, A; Greenhouse, J; Iraci, N; Lewis, MG; Norelli, S; Savarino, A; Shytaj, IL; Yalley-Ogunro, J | 1 |
| Ingiliz, P; Ivanka, K; Krznaric, I; Martin, O; Obermeier, M; Patrick, I | 1 |
| Ambrosioni, J; Calmy, A; Daou, S; Merkler, D | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Horiba, M; Itoda, I; Koga, M; Komatsu, H; Mitsuya, H; Miyakawa, T; Naito, T; Nishijima, T; Oka, S; Shimbo, T; Takada, K; Tanabe, Y; Tei, M; Yamamoto, M | 1 |
| Blum, JD; Kiser, JJ; MacBrayne, CE | 1 |
| Duan, J; Freeling, JP; Ho, RJ; Koehn, J; Shu, C | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Allavena, C; Antinori, A; Arribas, JR; Babiker, AG; Chêne, G; Delfraissy, JF; George, EC; Grarup, J; Hudson, F; Jansson, PO; Molina, JM; Pozniak, A; Raffi, F; Richert, L; Saillard, J; Schwimmer, C; Van Leeuwen, R; Vella, S; Wallet, C | 1 |
| Carda-Broch, S; Casas-Breva, I; Esteve-Romero, J; Peris-Vicente, J; Villarreal-Traver, M | 1 |
| Bedimo, RJ; Castanon, R; Cutrell, J; Drechsler, H; Farukhi, I; Jain, M; Li, X; Maalouf, NM; Tebas, P; Zhang, S | 1 |
| Becker, A; Desprez, S; Froidure, M; Gagneux, M; Huguet, D; Leduc, D; Legout, L; Sifaoui, F; Vignoli, P | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Carleo, MA; Chirianni, A; Coppola, N; De Luca, A; Esposito, V; Guerra, G; Lucariello, A; Perna, A; Sangiovanni, V; Viglietti, R | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Aris, AB; Jaafar, J; Madhavi, G; Majid, ZA; Reddy, AV; Talib, J; Umar, K | 1 |
| Walter, M | 1 |
| Cuppone, AM; De Falco, G; Ekeruche-Makinde, J; Hijazi, K; Hold, GL; Iannelli, F; Kelly, CG; Pozzi, G; Shattock, R; Smith, K; Stincarelli, MA | 1 |
| Kato, S; Sudo, K; Takagi, R; Yamada, E | 1 |
| Berry, S; Ekeruche-Makinde, J; El-Omar, EM; Frank, B; Gwozdz, G; Hijazi, K; Hold, GL; Iannelli, F; Kelly, C; Mukhopadhya, I; Murray, GI; Pozzi, G; Shattock, R; Thomson, J | 1 |
| Arribas, JR; Babiker, A; Bernardino, JI; Buño, A; Castagna, A; Chene, G; De Wit, S; Gerstoft, J; Girard, PM; Katlama, C; Mallon, PW; Mocroft, A; Raffi, F; Reiss, P; Richert, L; Russell, C; Wallet, C | 1 |
| Balogh, A; Iakoubov, R; Kern, KE; Noe, S; Schmid, RM; Schwerdtfeger, C; Spinner, CD; Von Werder, A; Wolf, E; Zink, A | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Brown, TT; Chan, ES; Eron, JJ; Fichtenbaum, CJ; Klingman, KL; Landay, AL; Martinson, J; Mirmonsef, P; Ofotokun, I; Plants, J; Ribaudo, HJ; Taiwo, BO; Weitzmann, MN | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Borghetti, A; Castagna, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Galizzi, N; Gianotti, N; Gori, A; Maillard, M; Mondi, A; Poli, A | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Post, FA | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| Fujiwara, H; Hasegawa, N; Kato, S; Takagi, R; Tanabe, Y; Yamada, E | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Arribas, JR; Eron, JJ; Gathe, J; Hufkens, V; Lathouwers, E; Molina, JM; Negredo, E; Opsomer, M; Orkin, C; Petrovic, R; Van Landuyt, E; Vanveggel, S | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Ganase, B; Harrigan, PR; Harris, M; Hull, MW; Montaner, JSG; Watson, B | 1 |
| Cevik, M; Orkin, C | 1 |
| Clotet, B; Negredo, E | 1 |
| Castagna, A; Lazzarin, A; Spagnuolo, V | 1 |
| Deeks, ED | 1 |
| Borghetti, A; Castelli, F; Izzo, I; Lombardi, F; Maggiolo, F; Magro, P; Quiros-Roldan, E; Raffetti, E; Saracino, A | 1 |
| Höring, S; Löffler, B; Pletz, MW; Rößler, S; Schleenvoigt, BT; Weis, S | 1 |
| Alejos, B; Allavena, C; Arribas, JR; Bernardino, JI; de Miguel, R; Esteban-Cantos, A; Gisslén, M; Hoffmann, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Baettig, V; Battegay, M; Courlet, P; Delko, T; Marzolini, C | 1 |
| Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
| Baugh, B; Crauwels, HM; Hijzen, A; Opsomer, M; Van Landuyt, E; Vanveggel, S | 1 |
| Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
| Martìnez, E; Pulido, F | 1 |
| Curran, A; Navarro, J | 1 |
| Gómez Ayerbe, C; Palacios Muñoz, R; Santos González, J | 1 |
| Galindo Puerto, MJ | 1 |
| Fontecha, M; Luis Casado, J; Monsalvo, M; Vizcarra, P | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
| Brown, TT; Landay, A; Masters, MC; Miyahara, S; Robertson, K; Taiwo, BO; Vecchio, A | 1 |
| Alejos, B; Arribas, JR; Bernardino, JI; De Miguel, R; Esser, S; Esteban-Cantos, A; Goujard, C; Montejano, R; Raffi, F; Rodes, B; Rodriguez-Centeno, J; Sarmento-Castro, R; Schwimmer, C; Stella-Ascariz, N; Wallet, C | 1 |
| Boffito, M; Bonora, S; Cursley, A; D'Avolio, A; Di Perri, G; Dickinson, L; Fäetkenheuer, G; Gurjar, R; Molina, JM; Owen, A; Pozniak, A; Raffi, F; Richert, L; Stöhr, W; Vandekerckhove, L | 1 |
| Fulco, PP; Gomes, D; Leibrand Kaczmar, CR; Smith, T | 1 |
| Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
| Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
| Bailey, AC; Mackie, N; Muir, D; Ring, K | 1 |
| Caldwell, A; Cuppone, AM; Dereuddre-Bosquet, N; Desjardins, D; Frank, B; Grand, RL; Gwozdz, G; Hijazi, K; Iannelli, F; Kelly, C; Mukhopadya, I; Pozzi, G; Santoro, F; Scala, C; Smith, KA | 1 |
| Bickel, M; Gillor, D; Grunwald, S; Härter, G; Hoffmann, C; Krznaric, I; Mueller, MC; Müller, M; Postel, N; Roider, J; Römer, K; Schabaz, F; Schewe, K; Spinner, CD | 1 |
| Amador, C; de Zárraga, MA; Díez Martínez, M; Górgolas, M; Jarrín, I; Moreno, C; Navarro, M; Pérez-Elías, MJ; Pérez-Martínez, L; Ruiz-Algueró, M; Suárez-García, I; Viciana, P | 1 |
| Boffito, M; Girometti, N; Lander, F; McOwan, A; Nwokolo, N; Whitlock, G | 1 |
| Baugh, B; De Meyer, S; Ghys, A; Jezorwski, J; Lathouwers, E; Mohsine, EG; Van Landuyt, E; Weinsteiger, S | 1 |
| Baugh, B; Brown, K; El Ghazi, M; Huhn, GD; Jezorwski, J; Lathouwers, E; Mussini, C; Spinner, CD; Van Landuyt, E; Wilkin, A | 1 |
| Dunn, K; Hardy, H; Kassam, PT; Luo, D; Rogers, R; Seyedkazemi, S; Sheng, S; Simonson, RB | 1 |
| Best, BM; Hill, L; Momper, JD; Patel, N; Salama, E | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Castelnuovo, B; Hakim, J; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Mirembe, G; Mugerwa, H; Musaazi, J; Paton, NI; Siika, A; Tukamushabe, P; Walimbwa, S | 1 |
| Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Abel, S; Ajana, F; Avettand-Fenoel, V; Bauer, R; Calin, R; Chéret, A; Goujard, C; Lacombe, K; Lascoux, C; Lopez, P; Meiffrédy, V; Meyer, L; Morlat, P; Reynes, J; Rouzioux, C | 1 |
| Bossolasco, S; Bruzzesi, E; Carini, E; Castagna, A; Chiurlo, M; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Mastrangelo, A; Nozza, S; Poli, A; Ranzenigo, M; Spagnuolo, V; Termini, R | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Lamori, JC; Mounzer, K | 1 |
| Alcantarini, C; Bono, V; Bonora, S; Calcagno, A; Cannizzo, ES; Cusato, J; D'Avolio, A; De Nicolò, A; De Vivo, E; Di Perri, G; Ferrara, M; Ianniello, A; Marchetti, G; Nozza, S; Salvador, E; Trentalange, A; Trunfio, M | 1 |
| Brunet, L; Dunbar, M; Fusco, GP; Fusco, JS; McCurdy, LH; McNicholl, IR; Mounzer, K; Sension, M | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Cohen, CE; Garvey, L; Heskin, J; Leung, S; Naous, N; Oddie, PD | 1 |
| Cardoso, SW; Castro, T; Estrela, R; Grinsztejn, B; Oliveira, VG; Toledo, T; Torres, TS; Veloso, VG | 1 |
13 review(s) available for tenofovir and darunavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Decompressive Craniectomy; Dideoxynucleosides; Female; Humans; Intracranial Hypertension; Lopinavir; Medication Adherence; Meningoencephalitis; Organophosphonates; Sulfonamides; Tenofovir; Treatment Outcome | 2013 |
Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Gastric Bypass; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir | 2014 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Tenofovir; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
Drug-induced liver injury secondary to increased levonorgestrel exposure in a patient taking ritonavir.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Darunavir; Female; HIV Infections; Humans; Levonorgestrel; Ritonavir; Tenofovir | 2023 |
Pharmacokinetics of Antiretroviral Drugs in Older People Living with HIV: A Systematic Review.
Topics: Adenine; Adolescent; Aged; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; HIV Infections; Humans; Pharmaceutical Preparations; Raltegravir Potassium; Tenofovir; Young Adult | 2023 |
35 trial(s) available for tenofovir and darunavir
| Article | Year |
|---|---|
The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Young Adult | 2010 |
Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2010 |
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Aged; Darunavir; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mutation; Organophosphonates; Polymorphism, Genetic; Pyrimidinones; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2011 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kidney; Kidney Function Tests; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir; Viral Load | 2013 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Darunavir; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tenofovir; Treatment Outcome | 2014 |
The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health.
Topics: Adenine; Adult; Bone Density; Darunavir; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Tenofovir | 2014 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
[In Process Citation].
Topics: Age Factors; Aged; Comorbidity; Cross-Sectional Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Middle Aged; Raltegravir Potassium; Tenofovir | 2015 |
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Biomarkers; Bone Density; Bone Diseases, Metabolic; CD4 Lymphocyte Count; Comorbidity; Darunavir; Drug Therapy, Combination; Emtricitabine; Europe; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Osteopetrosis; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2015 |
Neither boosted elvitegravir nor darunavir with emtricitabine/tenofovir disoproxil fumarate increase insulin resistance in healthy volunteers: results from the STRIBILD-IR study.
Topics: Adult; Darunavir; Emtricitabine; Healthy Volunteers; Humans; Insulin Resistance; Prospective Studies; Quinolones; Tenofovir; Triglycerides | 2016 |
Differential CD4+ cell count increase and CD4+ : CD8+ ratio normalization with maraviroc compared with tenofovir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cyclohexanes; Darunavir; Double-Blind Method; Emtricitabine; Female; Flow Cytometry; HIV Infections; Humans; Male; Maraviroc; Placebos; Prospective Studies; Tenofovir; Treatment Outcome; Triazoles | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppr
Topics: Adult; Cobicistat; Darunavir; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Tenofovir; Treatment Outcome; Viral Load | 2018 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
Topics: Adult; Aged; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Male; Middle Aged; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Topics: Adenine; Adult; Alanine; Area Under Curve; Biological Availability; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult | 2019 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Medication Adherence; Tenofovir | 2018 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Limited correlation between systemic biomarkers and neurocognitive performance before and during HIV treatment.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Biomarkers; Darunavir; Double-Blind Method; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Male; Maraviroc; Ritonavir; Tenofovir | 2020 |
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Topics: Adult; Aged; Anti-Retroviral Agents; Cross-Sectional Studies; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Telomere; Tenofovir | 2019 |
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001
Topics: Adult; Anti-HIV Agents; Constitutive Androstane Receptor; Darunavir; Emtricitabine; Female; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Raltegravir Potassium; Ritonavir; Tenofovir; Viral Load | 2020 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Sequence Analysis, DNA; Tablets; Tenofovir; Viral Load | 2021 |
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)
Topics: Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Tablets; Tenofovir | 2020 |
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Darunavir; Drug Resistance; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult; Zidovudine | 2021 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; RNA; Tenofovir; Viral Load | 2022 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
47 other study(ies) available for tenofovir and darunavir
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Chemistry, Pharmaceutical; Clinical Trials as Topic; Congresses as Topic; Darunavir; Drugs, Investigational; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Peptide Fragments; Pyrimidines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Rilpivirine; Societies, Scientific; Sulfonamides; Tenofovir; Zalcitabine | 2005 |
Expanded postexposure prophylaxis for simultaneous multiple source HIV exposure in a health-care worker.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Darunavir; Deoxycytidine; Emtricitabine; Enfuvirtide; Female; Fingers; HIV Envelope Protein gp41; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Middle Aged; Needlestick Injuries; Occupational Diseases; Organophosphonates; Peptide Fragments; Post-Exposure Prophylaxis; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir | 2010 |
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Topics: Adenine; Adult; Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Typing; Mutation; Organophosphonates; Ritonavir; RNA, Viral; Sulfonamides; Tenofovir; Treatment Outcome; Virus Replication | 2011 |
Analysis of resistance testing in South Trinidad.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Mutation; Organophosphonates; Patient Compliance; Sulfonamides; Tenofovir; Trinidad and Tobago | 2010 |
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
Topics: Adenine; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Flow Cytometry; Fluorescent Antibody Technique; Macaca mulatta; Maraviroc; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Simian Acquired Immunodeficiency Syndrome; Sulfonamides; T-Lymphocyte Subsets; Tenofovir; Triazoles; Viral Load; Viremia | 2012 |
Sexually transmitted infection with an immune-escape mutant hepatitis B virus in an hepatitis B virus-vaccinated individual with acute HIV-hepatitis C virus infection.
Topics: Acute Disease; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; HIV Seropositivity; Homosexuality, Male; Humans; Male; Organophosphonates; Sulfonamides; Tenofovir; Treatment Outcome; Unsafe Sex; Viral Load | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.
Topics: Adenine; Animals; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Lipids; Macaca nemestrina; Oligopeptides; Organophosphonates; Pyridines; Sulfonamides; Tenofovir | 2014 |
Use of micellar liquid chromatography to analyze darunavir, ritonavir, emtricitabine, and tenofovir in plasma.
Topics: Adenine; Anti-HIV Agents; Calibration; Chromatography, Liquid; Darunavir; Deoxycytidine; Emtricitabine; Humans; Micelles; Organophosphonates; Ritonavir; Sodium Dodecyl Sulfate; Sulfonamides; Tenofovir | 2014 |
Drug interactions between voriconazole, darunavir/ritonavir and tenofovir/emtricitabine in an HIV-infected patient treated for Aspergillus candidus lung abscess.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Aspergillosis; Aspergillus; Darunavir; Drug Interactions; Emtricitabine; HIV Infections; HIV Protease Inhibitors; Humans; Lung Abscess; Male; Ritonavir; Tenofovir; Treatment Outcome; Voriconazole | 2015 |
Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Development; Calcium; Cell Differentiation; Cell Line, Tumor; Collagen Type I; Cyclopropanes; Darunavir; Dideoxynucleosides; Gene Expression Regulation, Developmental; HIV-1; Humans; Nitriles; Osteosarcoma; p21-Activated Kinases; Pyridazines; Pyrimidines; RNA, Messenger; Tenofovir; Wnt3A Protein | 2015 |
Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics.
Topics: Chromatography, High Pressure Liquid; Darunavir; HIV Protease Inhibitors; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2015 |
Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs.
Topics: Adult; Anti-HIV Agents; Biological Transport; Cell Line; Cell Line, Tumor; Cervix Uteri; Darunavir; Drug Resistance; Drug Synergism; Female; Gene Expression Regulation; Humans; Membrane Transport Proteins; Middle Aged; Organ Culture Techniques; Pyrimidines; Tenofovir; Vagina | 2015 |
Determination of abacavir, tenofovir, darunavir, and raltegravir in human plasma and saliva using liquid chromatography coupled with tandem mass spectrometry.
Topics: Anti-Retroviral Agents; Calibration; Chromatography, Liquid; Darunavir; Dideoxynucleosides; Drug Monitoring; Humans; Ions; Limit of Detection; Mass Spectrometry; Raltegravir Potassium; Reproducibility of Results; Saliva; Solvents; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Temperature; Tenofovir | 2015 |
Drug transporter gene expression in human colorectal tissue and cell lines: modulation with antiretrovirals for microbicide optimization.
Topics: Aged; Anti-Infective Agents; Caco-2 Cells; Darunavir; Epithelial Cells; Female; Gene Expression; Gene Expression Profiling; Humans; Intestinal Mucosa; Male; Membrane Transport Proteins; Middle Aged; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tenofovir | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Emtricitabine; HIV; Humans; Lamivudine; Ritonavir; Tenofovir; United Kingdom | 2016 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Darunavir; Dideoxynucleosides; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protein Binding; Raltegravir Potassium; Saliva; Tandem Mass Spectrometry; Tenofovir | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4-CD8 Ratio; Cohort Studies; Darunavir; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Randomized Controlled Trials as Topic; Ritonavir; Telomere; Tenofovir | 2018 |
Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Bariatric Surgery; Chromatography, Liquid; Darunavir; Emtricitabine; Female; Gastric Bypass; HIV Infections; Humans; Obesity; Plasma; Tandem Mass Spectrometry; Tenofovir | 2018 |
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir | 2018 |
Pharmacology of Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; Drug Interactions; Humans; Tenofovir | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir; Treatment Outcome | 2018 |
Symtuza
Topics: Anti-HIV Agents; Darunavir; Drug Combinations; HIV Infections; Humans; Tenofovir | 2018 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Darunavir; Directly Observed Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Ritonavir; Tenofovir; Treatment Outcome | 2020 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
HIV-1 superinfection in a patient with known HIV-2 - A case report.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; HIV-2; Humans; Male; Middle Aged; Superinfection; Tenofovir; Treatment Outcome | 2020 |
Topics: Administration, Intravaginal; Animals; Biological Transport; Cell Line, Tumor; Darunavir; Disease Models, Animal; Drug Compounding; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Macaca fascicularis; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tenofovir; Tissue Distribution; Up-Regulation; Vagina | 2020 |
COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coinfection; Coronavirus Infections; COVID-19; Darunavir; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Survival Analysis; Tenofovir; Viral Load | 2020 |
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
Topics: Adult; Anti-HIV Agents; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Spain; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Homosexuality, Male; Humans; London; Male; Retention in Care; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2020 |
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis.
Topics: Adolescent; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Viral Load | 2021 |
Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.
Topics: Aged; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chromatography, Liquid; Cobicistat; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Pyridones; Tandem Mass Spectrometry; Tenofovir | 2021 |
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir | 2021 |
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
Topics: Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Tenofovir; Weight Gain | 2022 |
Inflammation and intracellular exposure of dolutegravir, darunavir, tenofovir and emtricitabine in people living with HIV.
Topics: Anti-HIV Agents; Darunavir; Emtricitabine; HIV Infections; Humans; Inflammation; Interleukin-6; Lipopolysaccharide Receptors; Lipopolysaccharides; Tenofovir | 2023 |
Immune response to ART initiation in advanced HIV infection.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunity; Tenofovir | 2023 |